Recursion Pharmaceuticals (RXRX) News Today $6.35 +0.41 (+6.90%) Closing price 03/14/2025 04:00 PM EasternExtended Trading$6.34 -0.01 (-0.16%) As of 03/14/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Up 4.6% - Still a Buy?Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Up 4.6% - What's Next?March 14 at 3:38 PM | marketbeat.comRecursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Down 3.2% - Time to Sell?Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 3.2% - Should You Sell?March 13 at 3:11 PM | marketbeat.comRecursion Pharmaceuticals: Stretched Thin And Chasing UnicornsMarch 12, 2025 | seekingalpha.comRecursion Pharmaceuticals (NASDAQ:RXRX) Trading Down 1.3% - Here's What HappenedRecursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 1.3% - Here's What HappenedMarch 12, 2025 | marketbeat.comJim Cramer on Recursion Pharmaceuticals, Inc. (RXRX): ‘We’re Going To Have To Hold Off’March 12, 2025 | insidermonkey.comRecursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Down 1.1% - What's Next?Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 1.1% - Here's WhyMarch 11, 2025 | marketbeat.comCathie Wood’s ARK Investment buys 35K shares of Recursion Pharmaceuticals todayMarch 11, 2025 | markets.businessinsider.comRecursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 6.9% - Should You Sell?Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Down 6.9% - Should You Sell?March 10, 2025 | marketbeat.comWhy Recursion Pharmaceuticals Stock Is Sinking TodayMarch 10, 2025 | fool.comApril 25th Options Now Available For Recursion Pharmaceuticals (RXRX)March 8, 2025 | nasdaq.comIs This Beaten-Down Artificial Intelligence (AI) Stock a Buy?March 8, 2025 | fool.comRecursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Up 2.1% - What's Next?Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Up 2.1% - Should You Buy?March 7, 2025 | marketbeat.com4 Things You Need to Know if You Buy Recursion Pharmaceuticals Stock TodayMarch 7, 2025 | fool.comThis Biotech Stock Could Be the Best Investment of the DecadeMarch 7, 2025 | fool.comRecursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Up 1.4% - Time to Buy?Recursion Pharmaceuticals (NASDAQ:RXRX) Trading 1.4% Higher - What's Next?March 6, 2025 | marketbeat.comVestmark Advisory Solutions Inc. Has $5.71 Million Stock Holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)Vestmark Advisory Solutions Inc. increased its holdings in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 15.3% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 845,154 shares of the company's stoMarch 6, 2025 | marketbeat.comDown Over 40%, Is Recursion Pharmaceuticals a Buy on the Dip?March 6, 2025 | fool.com49,273 Shares in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Purchased by SBI Securities Co. Ltd.SBI Securities Co. Ltd. acquired a new position in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 49,273 shares of the company'sMarch 6, 2025 | marketbeat.comNews Flash: Analysts Just Made A Sizeable Upgrade To Their Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) ForecastsMarch 6, 2025 | finance.yahoo.comRecursion Pharmaceuticals (NASDAQ:RXRX) Trading 0.3% Higher - Here's WhyRecursion Pharmaceuticals (NASDAQ:RXRX) Shares Up 0.3% - What's Next?March 5, 2025 | marketbeat.comRecursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 5.1% - Here's WhyRecursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 5.1% - Here's WhyMarch 4, 2025 | marketbeat.comRecursion Pharmaceuticals (NasdaqGS:RXRX) Surges 6% Following US$500 Million Follow-On Equity OfferingMarch 4, 2025 | finance.yahoo.comRecursion Pharmaceuticals (NASDAQ:RXRX) Trading Down 5.3% Following Weak EarningsRecursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 5.3% on Disappointing EarningsMarch 3, 2025 | marketbeat.comRecursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Q4 2024 Earnings Call TranscriptMarch 3, 2025 | insidermonkey.comRecursion Pharma Gets A Price-Target Cut After Q4 Miss: Retail Bearish Even As Cathie Wood's Ark Buys The DipMarch 3, 2025 | msn.comRecursion Pharmaceuticals (RXRX) Gets a Hold from TD CowenMarch 1, 2025 | markets.businessinsider.comRecursion Pharmaceuticals (NASDAQ:RXRX) Price Target Lowered to $6.00 at Leerink PartnersLeerink Partners lowered their price target on Recursion Pharmaceuticals from $7.00 to $6.00 and set a "market perform" rating on the stock in a report on Friday.March 1, 2025 | marketbeat.comRecursion Pharmaceuticals (NASDAQ:RXRX) Given New $6.00 Price Target at Leerink PartnersLeerink Partners lowered their target price on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a "market perform" rating on the stock in a research note on Friday.February 28, 2025 | marketbeat.comRecursion Pharmaceuticals (NASDAQ:RXRX) Releases Quarterly Earnings Results, Misses Estimates By $0.17 EPSRecursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) announced its quarterly earnings data on Friday. The company reported ($0.53) earnings per share for the quarter, missing analysts' consensus estimates of ($0.36) by ($0.17). Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The firm had revenue of $4.60 million during the quarter, compared to analysts' expectations of $19.04 million. During the same quarter in the previous year, the firm earned ($0.42) earnings per share. Recursion Pharmaceuticals's revenue was down 57.8% on a year-over-year basis.February 28, 2025 | marketbeat.comRecursion Pharmaceuticals (NASDAQ:RXRX) Issues Quarterly Earnings ResultsRecursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) issued its earnings results on Friday. The company reported ($0.53) earnings per share for the quarter, missing analysts' consensus estimates of ($0.36) by ($0.17). The firm had revenue of $4.60 million for the quarter, compared to analyst estimates of $19.04 million. Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. Recursion Pharmaceuticals's quarterly revenue was down 57.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.42) earnings per share.February 28, 2025 | marketbeat.comRecursion Pharmaceuticals, Inc. (RXRX) Q4 2024 Earnings Call TranscriptFebruary 28, 2025 | seekingalpha.comRecursion Pharmaceuticals misses Q4 estimates, shares dipFebruary 28, 2025 | in.investing.comRecursion Pharmaceuticals price target lowered to $6 from $7 at LeerinkFebruary 28, 2025 | markets.businessinsider.comRecursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Down 3.8% on Disappointing EarningsRecursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 3.8% After Earnings MissFebruary 28, 2025 | marketbeat.comRecursion Pharmaceuticals (NASDAQ:RXRX) Shares Gap Down Following Weak EarningsRecursion Pharmaceuticals (NASDAQ:RXRX) Shares Gap Down After Earnings MissFebruary 28, 2025 | marketbeat.comRecursion Pharmaceuticals reports Q4 EPS (53c) vs. (42c) last yearFebruary 28, 2025 | markets.businessinsider.comRecursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial ResultsFebruary 28, 2025 | globenewswire.comRecursion Pharmaceuticals (NASDAQ:RXRX) Trading Down 1.3% - Should You Sell?Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 1.3% - Here's What HappenedFebruary 27, 2025 | marketbeat.comCathie Wood’s ARK Investment buys 103K shares of Recursion Pharmaceuticals todayFebruary 27, 2025 | markets.businessinsider.comSpotlight on Recursion Pharmaceuticals: Analyzing the Surge in Options ActivityFebruary 26, 2025 | benzinga.comRecursion Pharmaceuticals (NASDAQ:RXRX) Shares Up 4.6% - Here's WhyRecursion Pharmaceuticals (NASDAQ:RXRX) Trading 4.6% Higher - Here's What HappenedFebruary 26, 2025 | marketbeat.comARK Investment Management LLC Sells 422,788 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)ARK Investment Management LLC decreased its stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 1.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 32,346,398 shares of the company's stFebruary 26, 2025 | marketbeat.comRecursion Pharmaceuticals put volume heavy and directionally bearishFebruary 26, 2025 | markets.businessinsider.comRecursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Down 11.7% - Time to Sell?Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Down 11.7% - Time to Sell?February 25, 2025 | marketbeat.comRecursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Down 4.6% - What's Next?Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 4.6% - Here's WhyFebruary 24, 2025 | marketbeat.comRecursion to Report Fourth Quarter and Fiscal Year 2024 Business Updates and Financial Results on February 28thFebruary 24, 2025 | globenewswire.comRecursion Pharmaceuticals, Inc. (RXRX): The Best Performing Pharma Stock So Far in 2025?February 23, 2025 | insidermonkey.comRecursion Pharmaceuticals (NASDAQ:RXRX) Trading Down 4.6% - Time to Sell?Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 4.6% - Time to Sell?February 21, 2025 | marketbeat.comSudden Ascent: Is Recursion Pharmaceuticals NVIDIA's AI Favorite?February 21, 2025 | msn.comSudden Ascent: Is Recursion Pharmaceuticals NVIDIA’s AI Favorite?Recursion Pharmaceuticals' stock has soared due to Nvidia's continued investment, positioning the company as a leader in AI-driven drug discovery.February 21, 2025 | marketbeat.com Remove Ads Get Recursion Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RXRX and its competitors with MarketBeat's FREE daily newsletter. Email Address RXRX Media Mentions By Week RXRX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RXRX News Sentiment▼0.420.77▲Average Medical News Sentiment RXRX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RXRX Articles This Week▼108▲RXRX Articles Average Week Remove Ads Get Recursion Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RXRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Vaxcyte News Today Qiagen News Today Ascendis Pharma A/S News Today Roivant Sciences News Today Lantheus News Today Revolution Medicines News Today Legend Biotech News Today TG Therapeutics News Today Telix Pharmaceuticals Limited American Depositary Shares News Today BridgeBio Pharma News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RXRX) was last updated on 3/16/2025 by MarketBeat.com Staff From Our PartnersElon Warns “America Is Broke”. Trump’s Plan Inside.Elon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredYour Wealth is Under AttackHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredNvidia’s CEO: “This Will Be a Multitrillion-Dollar Industry."If you missed out on the big boom in Nvidia… Listen up, because according to Nvidia's own CEO… Elon Musk...Brownstone Research | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored[Revealed] Trump’s Plan to Protect Your Savings for the Deep StateDuring Trump's first term, gold skyrocketed 52.89%. And it's already surging before his second. Last yea...Genesis Gold Group | SponsoredDOGE could send 6 AI stocks through the roofStay alert for Elon Musk and the Department of Government Efficiency's next move … Expect an announcement f...Weiss Ratings | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredAlert: DOGE goes liveElon will most likely be at the helm of it all. And just days from now, could bring about the biggest econo...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Recursion Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Recursion Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RXRX Stock Alerts